$LUMO
Lumos Pharma Inc

2018 Q1 Form 10-Q Financial Statement

#000112623418000084 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $9.900M $2.761M
YoY Change 258.57% -51.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.300M $8.200M
YoY Change 1.22% -10.87%
% of Gross Profit
Research & Development $20.31M $15.73M
YoY Change 29.18% -28.32%
% of Gross Profit
Depreciation & Amortization $334.0K $360.0K
YoY Change -7.22% -39.5%
% of Gross Profit
Operating Expenses $28.61M $23.96M
YoY Change 19.4% -22.96%
Operating Profit -$18.71M -$21.20M
YoY Change -11.76% -16.52%
Interest Expense $13.00K $106.0K
YoY Change -87.74% 1414.29%
% of Operating Profit
Other Income/Expense, Net $396.0K -$25.00K
YoY Change -1684.0% -164.1%
Pretax Income -$18.31M -$21.22M
YoY Change -13.73% -16.29%
Income Tax $0.00 -$310.0K
% Of Pretax Income
Net Earnings -$18.31M -$20.91M
YoY Change -12.45% -11.83%
Net Earnings / Revenue -184.95% -757.44%
Basic Earnings Per Share -$0.49 -$0.72
Diluted Earnings Per Share -$4.463M -$6.531M
COMMON SHARES
Basic Shares Outstanding 37.16M shares 29.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.9M $118.2M
YoY Change 21.74% -33.6%
Cash & Equivalents $143.9M $118.2M
Short-Term Investments
Other Short-Term Assets $5.600M $9.000M
YoY Change -37.78% 221.43%
Inventory
Prepaid Expenses $5.762M $8.984M
Receivables
Other Receivables $10.68M
Total Short-Term Assets $160.2M $143.2M
YoY Change 11.91% -24.43%
LONG-TERM ASSETS
Property, Plant & Equipment $4.700M $6.466M
YoY Change -27.31% -38.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.54M $6.466M
YoY Change 217.65% -38.41%
TOTAL ASSETS
Total Short-Term Assets $160.2M $143.2M
Total Long-Term Assets $20.54M $6.466M
Total Assets $180.7M $149.6M
YoY Change 20.8% -25.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $9.618M
YoY Change -44.89% 216.49%
Accrued Expenses $14.50M $17.81M
YoY Change -18.56% 60.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $200.0K
YoY Change -50.0% 21.95%
Total Short-Term Liabilities $20.00M $27.97M
YoY Change -28.5% 82.76%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $200.0K
YoY Change -50.0% -55.85%
Other Long-Term Liabilities $7.000M $7.100M
YoY Change -1.41% -4.05%
Total Long-Term Liabilities $7.100M $7.297M
YoY Change -2.7% -6.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.00M $27.97M
Total Long-Term Liabilities $7.100M $7.297M
Total Liabilities $27.10M $35.27M
YoY Change -23.16% 52.61%
SHAREHOLDERS EQUITY
Retained Earnings -$237.4M -$186.4M
YoY Change 27.36% 79.13%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.090M
YoY Change 41.37%
Treasury Stock Shares 52.24K shares
Shareholders Equity $138.0M $114.4M
YoY Change
Total Liabilities & Shareholders Equity $180.7M $149.6M
YoY Change 20.8% -25.16%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$18.31M -$20.91M
YoY Change -12.45% -11.83%
Depreciation, Depletion And Amortization $334.0K $360.0K
YoY Change -7.22% -39.5%
Cash From Operating Activities -$14.68M -$13.01M
YoY Change 12.81% -33.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $35.00K
YoY Change -100.0% -87.54%
Acquisitions
YoY Change
Other Investing Activities $100.0K $0.00
YoY Change -100.0%
Cash From Investing Activities $83.00K -$13.00K
YoY Change -738.46% -101.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $155.0K $174.0K
YoY Change -10.92% -504.65%
Debt Paid & Issued, Net $54.00K
YoY Change -25.0%
Cash From Financing Activities -$224.0K -$228.0K
YoY Change -1.75% 686.21%
NET CHANGE
Cash From Operating Activities -$14.68M -$13.01M
Cash From Investing Activities $83.00K -$13.00K
Cash From Financing Activities -$224.0K -$228.0K
Net Change In Cash -$14.82M -$13.25M
YoY Change 11.83% -1617.75%
FREE CASH FLOW
Cash From Operating Activities -$14.68M -$13.01M
Capital Expenditures $0.00 $35.00K
Free Cash Flow -$14.68M -$13.04M
YoY Change 12.51% -34.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37155082 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29213488 shares
CY2018Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
261000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-18310000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180739000 USD
CY2018Q1 us-gaap Revenue From Grants
RevenueFromGrants
9384000 USD
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5762000 USD
CY2018Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
10682000 USD
CY2018Q1 us-gaap Assets
Assets
180739000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237417000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20314000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-18310000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1907000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
67502 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37155082 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29213488 shares
CY2018Q1 us-gaap Restructuring Reserve
RestructuringReserve
9000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14676000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13009000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
83000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-224000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-228000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14817000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13250000 USD

Files In Submission

Name View Source Status
0001126234-18-000084-index-headers.html Edgar Link pending
0001126234-18-000084-index.html Edgar Link pending
0001126234-18-000084.txt Edgar Link pending
0001126234-18-000084-xbrl.zip Edgar Link pending
a2018331-10qxex311.htm Edgar Link pending
a2018331-10qxex312.htm Edgar Link pending
a2018331-10qxex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nlnk-20180331.htm Edgar Link pending
nlnk-20180331.xsd Edgar Link pending
nlnk-20180331_cal.xml Edgar Link unprocessable
nlnk-20180331_def.xml Edgar Link unprocessable
nlnk-20180331_g1.jpg Edgar Link pending
nlnk-20180331_htm.xml Edgar Link completed
nlnk-20180331_lab.xml Edgar Link unprocessable
nlnk-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending